# A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention

> **NCT00271765** · PHASE2 · COMPLETED · sponsor: **Inotek Pharmaceuticals Corporation** · enrollment: 40 (—)

## Conditions studied

- Acute Myocardial Infarction

## Interventions

- **DRUG:** INO-1001

## Key facts

- **NCT ID:** NCT00271765
- **Lead sponsor:** Inotek Pharmaceuticals Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-01
- **Primary completion:** —
- **Final completion:** 2006-06
- **Target enrollment:** 40 (—)
- **Last updated:** 2006-11-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00271765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00271765, "A Study of INO-1001, an Intravenous PARP (Poly [ADP Ribose] Polymerase) Inhibitor in Acute Heart Attack Patients Undergoing Primary Percutaneous Coronary Intervention". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT00271765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*